NRS 695G.172
Required provision concerning coverage for early refills of topical ophthalmic products.

1.

A managed care organization which offers or issues a health care plan that provides coverage for prescription drugs shall not deny coverage for a topical ophthalmic product which is otherwise approved for coverage by the managed care organization when the insured, pursuant to NRS 639.2395, receives a refill of the product:

(a)

After 21 days or more but before 30 days after receiving any 30-day supply of the product;

(b)

After 42 days or more but before 60 days after receiving any 60-day supply of the product; or

(c)

After 63 days or more but before 90 days after receiving any 90-day supply of the product.

2.

The provisions of this section do not affect any deductibles, copayments or coinsurance authorized or required pursuant to the health care plan.

3.

An evidence of coverage subject to the provisions of this chapter which provides coverage for prescription drugs and that is delivered, issued for delivery or renewed on or after January 1, 2016, has the legal effect of including the coverage required by this section, and any provision of the evidence of coverage or renewal which is in conflict with this section is void.

4.

As used in this section, “topical ophthalmic product” means a liquid prescription drug which is applied directly to the eye from a bottle or by means of a dropper.

Source: Section 695G.172 — Required provision concerning coverage for early refills of topical ophthalmic products., https://www.­leg.­state.­nv.­us/NRS/NRS-695G.­html#NRS695GSec172.

695G.150
Authorization of recommended and covered health care services required. 695G.155
Requirements regarding issuance of health benefit plans and adjustment of costs. 695G.160
Written criteria concerning coverage of health care services and standards for quality of health care services. 695G.162
Required provision concerning coverage for services provided through telehealth. 695G.163
Coverage for prescription drugs: Provision of notice and information regarding use of formulary. 695G.164
Required provision concerning coverage for continued medical treatment. 695G.166
Required provision concerning coverage for prescription drug previously approved for medical condition of insured. 695G.167
Required provision concerning coverage for orally administered chemotherapy. 695G.168
Required provision concerning coverage for screening for colorectal cancer. 695G.170
Required provision concerning coverage for medically necessary emergency services 695G.171
Required provision concerning coverage for certain tests and vaccines relating to human papillomavirus 695G.172
Required provision concerning coverage for early refills of topical ophthalmic products. 695G.173
Required provision concerning coverage for treatment received as part of clinical trial or study. 695G.174
Required provision concerning coverage for management and treatment of sickle cell disease. 695G.175
Certain actions of managed care organization prohibited. 695G.177
Required provision concerning coverage for prostate cancer screening. 695G.1645
Required provision concerning coverage for autism spectrum disorders. 695G.1665
Required provision concerning coverage for prescription drugs irregularly dispensed for purpose of the synchronization of chronic medications. 695G.1713
Required provision concerning coverage for mammograms for certain women 695G.1715
Required provision concerning coverage for drug or device for contraception and related health services 695G.1716
Health care plan that includes coverage for maternity care must not deny coverage for gestational carrier 695G.1717
Coverage for certain services, screenings and tests relating to wellness
Last Updated

Jun. 24, 2021

§ 695G.172’s source at nv​.us